- Development of HFA-152a as an environmentally sustainable propellant for pressurized metered dose inhalers
- Back Page: Is asthma a risk factor for COVID-19? Answers are evolving and likely to be complex
- Cascade impactor stage groupings: Poor decisions from degraded data
- Point of View: Overcoming barriers to affordability of orally inhaled products while protecting innovation
- Nasal and trans-nasal lung deposition of aerosols
- Back Page: Poplar trees genetically modified not to damage air quality grow as well as non-modified trees
- The liability of fine particle dose (FPD)
- Back Page: The EFA’s Active Asthma and COPD Patients ACCESS Care Report
- Accelerating inhalation product development: Choosing between outsourcing and developing internal capabilities
- Dry powder inhalers—More than 170 years of development; Where to next?
- The regulatory landscape for OINDPs—the biggest shake-up in a generation?
- Point of View: Recommendations to a young scientist to pursue inhalation research
- Back Page: US FDA approves OTC, non-CFC-based Primatene® Mist; Patient advocacy groups object
- Defining the dosage strength for labeling of DPIs: Use, limitations and relevance of in vitro data
- An overview of general chapter development for oral and nasal drug products (OINDPs) at the US Pharmacopeia (USP): Part 2—Informative chapters <1601>, <1602>, <1603> and <1604>
- Back Page: The Teal Pumpkin Project helps children with food allergies celebrate Halloween safely
- Connected inhalers: Stakeholders’ potential benefits and possible concerns
- Progress in particle engineering science: Towards advanced dry powder inhalation systems
- Back Page: School-based telemedicine combined with in-school care helped children manage asthma
- Back Page: Reasons for e-cigarette use among US middle and high school students: The National Youth Tobacco Survey 2016
- Meeting expectations for FDA nasal spray Q3 structural equivalence
- Nebulizers: Past to present platforms and future possibilities (2018)
- An overview of general chapter development for oral and nasal drug products (OINDPs) at the US Pharmacopeia (USP): Part 1—Normative chapters <5>, <601>, <602>, <603> and <604>
- Back Page: Reducing carbon footprints of metered dose inhalers
- Back Page: Black children in US six times more likely to die of asthma
- Back Page: New system enables more donor lungs to be transplanted
- Back Page: NIH issues new guidelines for prevention of peanut allergy in children
- Back Page: Past Inhalation covers, with thanks to our three charter advertisers!
- Back Page: Lessons from UK asthma deaths: Improving asthma care
- Back Page: Comic books help educate kids about asthma and proper inhaler use
- Back Page: Inhalatorium: A website dedicated to the history of inhalation therapy
- Back Page: Bridges for the asthma achievement gap
- Back Page: Increasing participation in and improving outcomes from pMDI training
- Back Page: Modeling paradigms for orally inhaled drugs
- Back Page: Exercise induced bronchoconstriction: The role of inhaled therapy in identifying stimulus and mechanism
- Back Page: Leveraging digital health technology: Five ways to address barriers to inhaled medication adherence
- Back Page: Controlled release formulations for inhalation: Soon to appear?
- Back Page: On the design of comparator clinical studies
- Back Page: Why do we know so little about absorption pathways in the lung?
- Back Page: High maternal sugar intake during pregnancy associated with allergy and allergic asthma in children
- Regulatory considerations for cybersecurity and data privacy in digital health and medical applications and products
- The lung as a dissolution vessel?
- The impact of intratracheal aerosol technologies on preclinical pulmonary research
- The Good Cascade Impactor Practice (GCIP) Concept: A systematic approach to risk management of erroneous measurements in the assessment of inhaler emitted aerosol aerodynamic particle size distributions (APSDs)
- The Asthma Insight and Management survey
- The Abbreviated Impactor Measurement (AIM) and Efficient Data Analysis (EDA) concepts: Why they are important and how to work with them
- Simplifying OINDP regulations
- Significant restriction of the delivered dose uniformity criteria in the revised USP Chapter for Aerosols
- Significant advances in laboratory testing of orally inhaled products during the ten-year life of Inhalation
- Risk management for combination products
- Redundancy Based Development (RBD) for a dry powder inhaler
- Product development: Case study of an inhaled biologic
- Principles of nebulizer technology
- PK bioequivalence testing when between-batch variability is high: A multiple-batch proposal
- Particle design for respiratory drug delivery: Challenges and processing options
- Overlooked opportunities for nebulizers in inhalation product development
- Nebulizers: Past to present platforms and future possibilities (2016)
- Nebulizer testing
- MDI propellants
- Intranasal Vaccines: Protecting Public Safety
- Interaction of nanomaterials at the air-liquid interface of the lung
- Inhaled therapies for tuberculosis: A viable approach for spray-dried drugs delivered by handheld dry powder inhaler
- Inhalation toxicity of graphene and its derivatives
- Inhalation to the small airways
- Imaging techniques for dry powder inhaler capsules
- Human factors studies in the development of a new nasal delivery device
- Human factors and inhalation pharmaceuticals: Manifestations, mitigations and regulatory issues
- Good practices for Abbreviated Impaction Measurements (AIM) in dry powder inhalers (DPIs)
- Getting started with CFD
- Gene–environment interactions in asthma: Lessons for the development of new drugs for asthma
- Gaps in statistical approaches to control of delivered dose uniformity throughout product lifecycle
- Functional respiratory imaging (FRI): An alternative to pulmonary function tests (PFTs)
- Formulation concepts for small-volume nebulizers: Challenges and opportunities
- Evaluating the performance of orally inhaled products in the laboratory: Why clinically appropriate testing is important
- Evaluating the Alberta Throat: An innovation to support the acquisition of more clinically applicable aerosol aerodynamic particle size distribution (APSD) data in oral inhaled product (OIP) development
- Enhancing drug product portfolios for nasal aerosols and buccal spray delivery systems
- Elastomers in orally inhaled and nasal drug products, Part I: Elastomer selection and qualification
- E-cigarettes: Learnings for inhalation scientists
- Development of inhalable dry-powder formulations for low water-soluble products using spray-dried engineered particles
- Delivery of inhaled bronchodilators by breath-actuated jet nebulizer: The potential for improved adherence with clinical guidelines
- Delivering orally inhaled medications to the older patient with COPD and/or asthma: A challenge in both device design and clinical approach
- Critical evaluation of the revised and new USP chapters for aerosols: and [Pharm Forum 2011; 37(4)]
- The pressurized metered dose inhaler: Past, present and future perspectives
- Avoiding pitfalls obtaining inhalation patents at the European Patent Office
- Assessing the role of breathing simulators in OIP testing
- Trends in nasal delivery
- An Introduction to IPAC-RS
- Analytical instrumentation for solid state characterization of inhalable formulations
- Addressing the patient-device use interface: Why patient-friendly features are important
- US Payers and OINDPS
- Abbreviated Impactor Measurement (AIM) and Efficient Data Analysis (EDA) Concepts: A partnership for the assurance of Oral Inhaled Product (OIP) quality
- A “smart” move: The development of electronic devices for nasal aerosols
- Testing the equivalence of aerodynamic particle size distributions
- What is the future of HFA pMDIs? A patent-based perspective